

Resource Summary Report

Generated by [NIF](#) on Jul 28, 2026

CD14

RRID:AB_2743629

Type: Antibody

Proper Citation

BD Biosciences Cat# 746304, RRID:AB_2743629

Antibody Information

URL: http://antibodyregistry.org/AB_2743629

Proper Citation: BD Biosciences Cat# 746304, RRID:AB_2743629

Target Antigen: CD14

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD14

Description: This monoclonal targets CD14

Target Organism: human

Clone ID: M5E2

Antibody ID: AB_2743629

Vendor: BD Biosciences

Catalog Number: 746304

Record Creation Time: 20250820T060040+0000

Record Last Update: 20250820T230355+0000

Ratings and Alerts

No rating or validation information has been found for CD14.

No alerts have been found for CD14.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Lemieux A, et al. (2024) Enhanced detection of antigen-specific T cells by a multiplexed AIM assay. *Cell reports methods*, 4(1), 100690.

Dubé M, et al. (2023) Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIV-specific CD4+ and CD8+ T cells. *Cell host & microbe*, 31(9), 1507.

Nicolas A, et al. (2023) An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells. *iScience*, 26(1), 105904.

Sannier G, et al. (2023) A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile. *Cell reports. Medicine*, 4(3), 100955.

Tauzin A, et al. (2023) Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine. *Cell reports*, 42(1), 111998.

Tauzin A, et al. (2022) Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. *Cell host & microbe*, 30(1), 97.

Nayrac M, et al. (2022) Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. *Cell reports*, 39(13), 111013.

Anand SP, et al. (2021) Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. *Cell reports. Medicine*, 2(6), 100290.

Tauzin A, et al. (2021) A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. *Cell host & microbe*, 29(7), 1137.